From Earlier: FDA Grants TearLab Osmolarity System CLIA Waiver Categorization; Stock up 67%

TearLab Corporation

announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that, based on a supervisory review of the Company's appeal, the Agency has granted its petition for a waiver under CLlA for the TearLab® Osmolarity System. Upon the Company's submission of labeling acceptable to the Agency, the CLIA waiver will be issued. TearLab is currently trading at $2.08 or $0.84, a gain of 67.74%.